John Gardner1, Kunani Tuttle2, Kalani L Raphael2,3. 1. Pharmacy Section, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah. 2. Department of Internal Medicine, University of Utah Health, Salt Lake City, Utah. 3. Medicine Section, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.
Abstract
Background: Many medications are formulated with acid salts. Their effect on acid-base balance in CKD is unclear. Methods: We calculated the acid load (meq/d) from medications prescribed to 74 United States veterans with diabetes and CKD to identify agents with high potential acid load. We also determined cross-sectional associations between the acid load from medications and acid-base parameters after adjusting for demographics, eGFR, protein intake, and other confounders. Results: Of the 125 medications prescribed, 31 (25%) contained an acid salt. Metformin hydrochloride (15.4 meq/d at 2550 mg/d) and gabapentin hydrochloride (13.0 meq/d at 2700 mg/d) were identified as agents with a high potential acid load. Mean daily acid load from medications was 6.6 meq/d in the overall cohort, 14.2 meq/d in the high medication acid load group (≥7.7 meq/d, n=29), and 1.6 meq/d in the low medication acid load group (<7.7 meq/d, n=45). After adjusting for potential confounders, those in the high acid load group had 1.7 meq/L lower total carbon dioxide (CO2) and 2.2 meq/L higher anion gap than those in the low acid load group. Use of gabapentin alone was not associated with differences in total CO2 or anion gap. Use of metformin alone was associated with 0.7 meq/L lower total CO2 and 1.0 meq/L higher anion gap. Use of metformin with gabapentin was associated with 1.8 meq/L lower total CO2 and 2.4 meq/L higher anion gap. The higher anion gap was not explained by higher serum lactate levels. The acid load from medications was not associated with differences in urinary ammonium, titratable acid, or pH. Conclusions: Medications containing acid salts, particularly metformin hydrochloride and gabapentin hydrochloride, are sources of an exogenous acid load. These agents may influence serum total CO2 levels and serum anion gap in individuals with CKD. Clinical Trial registry name and registration number: Investigations of the Optimum Serum Bicarbonate Level in Renal Disease, NCT01574157.
Background: Many medications are formulated with acid salts. Their effect on acid-base balance in CKD is unclear. Methods: We calculated the acid load (meq/d) from medications prescribed to 74 United States veterans with diabetes and CKD to identify agents with high potential acid load. We also determined cross-sectional associations between the acid load from medications and acid-base parameters after adjusting for demographics, eGFR, protein intake, and other confounders. Results: Of the 125 medications prescribed, 31 (25%) contained an acid salt. Metformin hydrochloride (15.4 meq/d at 2550 mg/d) and gabapentin hydrochloride (13.0 meq/d at 2700 mg/d) were identified as agents with a high potential acid load. Mean daily acid load from medications was 6.6 meq/d in the overall cohort, 14.2 meq/d in the high medication acid load group (≥7.7 meq/d, n=29), and 1.6 meq/d in the low medication acid load group (<7.7 meq/d, n=45). After adjusting for potential confounders, those in the high acid load group had 1.7 meq/L lower total carbon dioxide (CO2) and 2.2 meq/L higher anion gap than those in the low acid load group. Use of gabapentin alone was not associated with differences in total CO2 or anion gap. Use of metformin alone was associated with 0.7 meq/L lower total CO2 and 1.0 meq/L higher anion gap. Use of metformin with gabapentin was associated with 1.8 meq/L lower total CO2 and 2.4 meq/L higher anion gap. The higher anion gap was not explained by higher serum lactate levels. The acid load from medications was not associated with differences in urinary ammonium, titratable acid, or pH. Conclusions: Medications containing acid salts, particularly metformin hydrochloride and gabapentin hydrochloride, are sources of an exogenous acid load. These agents may influence serum total CO2 levels and serum anion gap in individuals with CKD. Clinical Trial registry name and registration number: Investigations of the Optimum Serum Bicarbonate Level in Renal Disease, NCT01574157.
Authors: Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray Journal: J Am Soc Nephrol Date: 2008-11-12 Impact factor: 10.121
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Edgard Wehbe; Rupesh Raina; James F Simon; Titte R Srinivas; Anil Jain; Martin J Schreiber; Joseph V Nally Journal: Clin J Am Soc Nephrol Date: 2011-09-01 Impact factor: 8.237
Authors: Kalani L Raphael; Sarah Gilligan; Thomas H Hostetter; Tom Greene; Srinivasan Beddhu Journal: Clin J Am Soc Nephrol Date: 2017-11-16 Impact factor: 8.237
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Mirela Dobre; Wei Yang; Qiang Pan; Lawrence Appel; Keith Bellovich; Jing Chen; Harold Feldman; Michael J Fischer; L L Ham; Thomas Hostetter; Bernard G Jaar; Radhakrishna R Kallem; Sylvia E Rosas; Julia J Scialla; Myles Wolf; Mahboob Rahman Journal: J Am Heart Assoc Date: 2015-04-20 Impact factor: 5.501
Authors: Sunghwan Kim; Jie Chen; Tiejun Cheng; Asta Gindulyte; Jia He; Siqian He; Qingliang Li; Benjamin A Shoemaker; Paul A Thiessen; Bo Yu; Leonid Zaslavsky; Jian Zhang; Evan E Bolton Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971